Digitization in cell and gene therapy (CGT) manufacturing is increasing traceability and efficiency but also raising cybersecurity risks, highlighting the sector’s emerging critical infrastructure status. UK researchers emphasize safeguarding quality control, regulatory compliance, and data protection in highly automated processes, especially with point-of-care manufacturing. Meanwhile, leading academic CGT institutes like Roswell Park CCC expand GMP manufacturing capacity and integrate industry talent to accelerate cell therapy translation from ideation to trials, highlighting the sector's maturation and increased clinical throughput.